Europe - Euronext Brussels - EBR:TUB - BE0003823409 - Common Stock
The current stock price of TUB.BR is 220.5 EUR. In the past month the price increased by 1.4%. In the past year, price increased by 44.56%.
ChartMill assigns a technical rating of 8 / 10 to TUB.BR. When comparing the yearly performance of all stocks, TUB.BR is one of the better performing stocks in the market, outperforming 84.61% of all stocks.
ChartMill assigns a fundamental rating of 3 / 10 to TUB.BR. While TUB.BR has a great health rating, there are worries on its profitability.
Over the last trailing twelve months TUB.BR reported a non-GAAP Earnings per Share(EPS) of 2.08. The EPS increased by 3.02% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | 4.79% | ||
| ROE | 4.79% | ||
| Debt/Equity | 0 |
6 analysts have analysed TUB.BR and the average price target is 235.11 EUR. This implies a price increase of 6.63% is expected in the next year compared to the current price of 220.5.
Financiere de Tubize SA is a holding company, which engages in investing in the biopharmaceuticals industry. The company is headquartered in Brussels, Bruxelles-Capitale. The firm holds minor capital in UCB SA. UCB is a Belgian pharmaceutical and specialty chemical company that specializes in two therapeutic areas: diseases of the central nervous system (CNS) and immunology. UCB, together with its subsidiaries, has research and development facilities in Belgium, Germany, Japan, the United Kingdom and the United States. The firm promotes the development of a sustainable biopharma ecosystem in Belgium and possibly in other geographic areas relevant to UCB.
FINANCIERE DE TUBIZE
Allee de la Recherche, 60
Brussels BRUXELLES-CAPITALE BE
Employees: 3
Phone: 320497515208
Financiere de Tubize SA is a holding company, which engages in investing in the biopharmaceuticals industry. The company is headquartered in Brussels, Bruxelles-Capitale. The firm holds minor capital in UCB SA. UCB is a Belgian pharmaceutical and specialty chemical company that specializes in two therapeutic areas: diseases of the central nervous system (CNS) and immunology. UCB, together with its subsidiaries, has research and development facilities in Belgium, Germany, Japan, the United Kingdom and the United States. The firm promotes the development of a sustainable biopharma ecosystem in Belgium and possibly in other geographic areas relevant to UCB.
The current stock price of TUB.BR is 220.5 EUR. The price increased by 1.15% in the last trading session.
FINANCIERE DE TUBIZE (TUB.BR) has a dividend yield of 0.32%. The yearly dividend amount is currently 0.97.
TUB.BR has a ChartMill Technical rating of 8 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
6 analysts have analysed TUB.BR and the average price target is 235.11 EUR. This implies a price increase of 6.63% is expected in the next year compared to the current price of 220.5.
FINANCIERE DE TUBIZE (TUB.BR) has a market capitalization of 9.81B EUR. This makes TUB.BR a Mid Cap stock.